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Aim. To evaluate the diagnostic value of quantification of liver tumor microvascularization using contrast-enhanced ultrasound
(CEUS) measured continuously from the arterial phase to the late phase (3 minutes). Material and Methods. We present a
retrospective analysis of 20 patients with malignant (𝑛 = 13) or benign (𝑛 = 7) liver tumors. The tumors had histopathologically
been proven or clearly identified using contrast-enhanced reference imaging with either 1.5 TMRI (liver specific contrast medium)
or triphase CT and follow-up. CEUS was performed using a multifrequency transducer (1–5MHz) and a bolus injection of 2.4mL
sulphur hexafluoride microbubbles. A retrospective perfusion analysis was performed to determine TTP (time-to-peak), RBV
(regional blood volume), RBF (regional blood flow), and Peak.Results. Statistics revealed a significant difference (𝑃 < 0.05) between
benign and malignant tumors in the RBV, RBF, and Peak but not in TTP (𝑃 = 0.07). Receiver operating curves (ROC) were
generated for RBV, RBF, Peak, and TTP with estimated ROC areas of 0.97, 0.96, 0.98, and 0.76, respectively. Conclusion. RBV,
RBF, and Peak continuously measured over a determined time period of 3 minutes could be of valuable support in differentiating
malignant from benign liver tumors.
1. Introduction
The radiomorphological differentiation between benign and
malignant liver tumors with contrast-enhanced ultrasound is
based on a continuous, dynamic evaluation ofmicrovascular-
ization of the tumor [1] and has been shown to be extremely
reliable [2, 3].
Malignant liver tumors (HCC, CCC, and metastasis)
often have an irregular, sometimes chaotic, early-arterial
and arterial (15–45 secs) microvascularization showing a
hyperenhancement or rim enhancement [4] in the arterial
phase and a hypoechogenic pattern in the portal-venous
and the late (2–5mins) venous phases [4–6]. Metastasis
can be hypovascular (e.g., adenocarcinoma) with necrotic,
nonenhanced areas or hypervascular (e.g., neuroendocrine
tumors) with complete or partial hyperenhancement in the
arterial phase. A common feature of almost all metastases is
hypo- or nonenhancement in the portal and late phases [7–9].
Most benign hepatic lesions (haemangioma, focal nodu-
lar hyperplasia, and adenoma) show a rapid enhancement
in the arterial phase with a prolonged enhancement in the
late venous phase. They display mainly not only hypere-
chogenic but also isoechogenic patterns in the late phase
[4–6]. Classical patterns include nodular, wheel-spike, or
mixed accumulations as seen in haemangioma, focal nodular
hyperplasia (FNH), and adenoma, respectively [5].
Theuse of the 2nd generation contrastmedium, for exam-
ple, sulphur hexafluoride microbubbles (SonoVue, Bracco,
Italy), enables the detection of strictly intravascular, capillary
microvascularization from the early-arterial phase to the late
phase [10]. Continuously recorded images can be used for a
computer-assisted perfusion analysis.
Histopathologic findings obtained from percutaneous
biopsy or surgical specimens are recommended as the gold
standard in the characterization of malignant liver tumors.
The imaging techniques contrast-enhanced CT (ceCT) and
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Table 1: Characteristics of the study population.
𝑛 Mean age Min/max age Female
Benign 7 48 31/75 5
Malignant 13 62 51/72 3
All 20 57 31/75 8
contrast-enhanced MRI (ceMRI) have been proven valuable
in the characterization of benign liver tumors. The use
of liver specific contrast medium is preferable, and long-
term radiographic follow-up is recommended to confirm the
stability of the lesion.
Recommendations for the characterization of hepato-
cellular carcinoma (HCC) are different and depend on the
size of the lesion [11, 12]. These have been issued in a
guideline from the World Federation for Ultrasound in
Medicine and Biology and the European Federation of
Societies for Ultrasound in Medicine and Biology [11] based
on the DEGUM (Deutsche Gesellschaft fu¨r Ultraschall in der
Medizin) multicenter study findings, which emphasizes the
value of CEUS in the diagnostic of focal liver lesions [2].
Therefore, the aim of this pilot study was to, for the first
time, quantify the perfusion of histopathologically proven or
radiomorphologically (ceCT/ceMRI) clearly identified liver
tumors over a determined time period of 3 minutes and
to evaluate the diagnostic value of the calculated perfusion
parameters.
2. Materials and Methods
This study comprised 20 patients, of whom 13 had malignant
hepatic lesions and 7 had benign hepatic lesions. The mean
age of the patients withmalignancy was 62.39 (SD 7.54) years,
and for benignity it was 47.96 (SD 14.49) years. Eight patients
were females (Table 1).
After undergoing CEUS, the malignancy was confirmed
by histopathology in 5 cases and by clinicoradiological
follow-up in 8 cases: ceMRI in 1 case, ceCT in 3 cases, and
a combination of ceCT and ceMRI in the remaining 4 cases.
Using ceMRI, benign lesions were confirmed in 6 out of
7 cases, while ceCT was used in the last case (adenoma).
Imaging follow-up was performed for a minimum period of
6 months. In addition, all images were separately reviewed
by an independent experienced radiologist to confirm the
diagnosis of benign/malignant lesions.
Before the procedures, the patient was adequately
informed about MRI and CT as well as CEUS, and his/her
consent was granted in writing.There were no contrastmedia
intolerances. Approval for this study was obtained from the
local ethical board.
Patients with impaired renal function, preexisting strong
allergic reactions, and decompensated cardiac failure as
well as contraindications for the administration of contrast
medium were not included in the study.
2.1. US/CEUS. At first, all patients underwent detailed B-
scan ultrasound (US). The sonographic examination was
performed by an experienced examiner (more than 10.000
abdominal sonographic examinations were done) using a
high-end ultrasound machine (LOGIQ E9, GE) and a mul-
tifrequency transducer (1–5MHz, GE Healthcare, Chalfont
St. Giles, UK). The whole liver parenchyma was scanned
in digital cine sequences using the sweep technique in a
transversal and sagittal plane. Color-codedDoppler sonogra-
phy (CCDS) was used for the evaluation of the unenhanced
tumor vascularization. The parameters were optimized for
low flow; adapted pulse repetition frequency was selected,
less than 1500Hz. A wall filter was used to reduce motion
artifacts.
Following the B-mode and CCDS evaluation of the
main tumor lesion, dynamic contrast-enhanced ultrasound
examination was carried out with Phase Inversion Technique
or Amplitude Modulation in true detection mode, as well
as parallel imaging of B-scan and CEUS during the arterial,
portal-venous, and late phases for up to 3 minutes.
As ultrasonic second generation contrast agents, sulphur
hexafluoride microbubbles (SonoVue, Bracco, Germany)
were used. An intravenous bolus of 2.4mL SonoVue was
applied followed by a bolus of 10mL saline injected through
a 20–18G peripheral cubital cannula. Injection was done
by the same assistant in all cases. Digital sequences were
recorded as DICOM and afterwards transformed to Audio
Video Interleaving (AVI) format.
Retrospectively, one independent examiner used the
quantification software QONTRAST (Bracco, Milan, Italy)
to obtain contrast-enhanced sonographic perfusion maps for
each lesion.The examiner was blinded for the corresponding
imaging by CT, MRI, and histology of tumors. QONTRAST
is dedicated perfusion quantification software designed for
the evaluation of tissue perfusion obtained using contrast-
enhanced ultrasound examination in real time.Therefore, an
analysis of tissue perfusion based on signal video intensity
changes over the timewas performed.The software calculates
time-intensity curves on a pixel-by-pixel basis. Calculated
curves are then fitted to parametric curves and, as a result,
parametric maps are obtained. Parametric maps are easy-
to-interpret color images describing different aspects of the
organ perfusion.
The parameters described in this study are the peak of the
signal intensity (Peak), the time-to-peak (TTP) which repre-
sents the time of arrival of the contrast agent to its maximum,
the regional blood volume (RBV)which is proportional to the
area under the curve, and the additional calculation of the
regional blood flow (RBF).
3. Statistics
Besides descriptive statistics, the nonparametric Mann-
Whitney test to compare perfusion parameters was used.
The level of significance was 𝑃 < 0.05. For each perfusion
measurement, we estimated the area under the empirical
receiver operating characteristic curve (AUC) to evaluate the
accuracy of separatingmalignant lesions frombenign lesions.
95% confidence intervals are computed for each AUC with
Radiology Research and Practice 3
Table 2: Size of the lesions (in mm) and their perfusion parameters.
𝑛 Size (SD) Min/max size Peak (SD) TTP (SD) RBV (SD) RBF (SD)
Adenoma 1 35 NA 52.6 20.4 4818.5 70.1
CCC 3 65 (22) 50/90 9.4 (5.0) 87.0 (48.8) 920.1 (290.5) 9.9 (4.9)
FNH 2 33 (3) 31/35 51.8 (0.1) 29.3 (11.4) 4660.3 (439.0) 67.3 (2.2)
Haemangioma 4 27 (12) 14/41 45.7 (9.3) 30.3 (6.8) 4426.8 (2050.3) 58.8 (16.2)
HCC 5 66 (26) 46/111 21.5 (12.5) 46.5 (36.5) 1258.0 (576.6) 25.6 (15.4)
Liposarcoma 1 45 NA 3.4 122.1 579.5 3.3
Metastasis 4 50 (25) 28/85 26.5 (14.9) 47.7 (36.8) 2036.9 (1327.8) 33.2 (19.6)
Benign lesions: focal nodular hyperplasia (FNH), adenoma, and haemangioma. Malignant lesions: hepatocellular carcinoma (HCC), cholangiocellular
carcinoma (CCC), metastases, and liposarcoma. SD: standard deviation.
Delong’s method [13]. For data analysis, the R programming
language (R version 3.0.1) and the pROC package [14] were
used.
4. Results
A dual mode examination (real-time B-mode and CEUS) of
the echogenicity and microvascularization was continuously
recorded for 3 minutes in all 20 cases. The entire volumes of
the tumors were captured, and there were no artifacts. It was
not necessary to repeat the injection of contrast media. The
evaluation of the echogenicity in B-mode did not reveal any
clear patterns for the identification of the tumors. Likewise,
the color-coded Doppler flow measurement, adapted for low
flow, did not show a specific pattern of vascularization for a
definite diagnosis.
Only the use of CEUS enabled the discrimination
between malignant and benign tumors. All benign lesions
(7 out of 20) showed a continuous contrast enhancement
until the late phase. This enhancement appeared nodular for
haemangioma and revealed vessels radiating from the central
artery to the periphery for FNH. The adenoma showed an
enhancement from the tumor border to the center.
All malignant lesions (13 out of 20) showed washout
beginning in the portal-venous phase and increasing through
the late phase.Metastases showed a circular rim enhancement
in the arterial phase. Hepatocellular carcinoma had a non-
homogeneous, sometimes chaotic, pattern of vascularization,
and cholangiocellular carcinoma showed a nonhomogeneous
parenchyma.
The tumor size ranged from 28 to 111mm (mean 59mm,
SD 23) for malignant lesions and from 14 to 41mm (mean
30mm, SD 9) for benign lesions. Three of the 13 malignant
lesions and 4 of the 7 benign lesions were located in the left
lobe. For detailed information about the size of the lesions
and their perfusion, see Table 2.
The analysis of dynamic microvascularization showed
significant differences between malignant and benign lesions
regarding RBV, RBF, and Peak (Table 3). Benign lesions
showed significantly higher signal intensity (Peak), a higher
blood volume (RBV), and a stronger blood flow (RBF).
Regarding TTP (time-to-peak), there was a high range with
a tendency towards higher TTP for malignant lesions but
Table 3: Differences in microvascularization between benign and
malignant lesions.
Benign Malignant 𝑃
Peak (SD) 48.4 (7.4) 18.9 (13.3) <0.001
TTP (SD) 28.6 (7.6) 62.1 (42.5) =0.07
RBV (SD) 4549.5 (1469.8) 1367.5 (906.5) <0.001
RBF (SD) 62.8 (12.6) 22.6 (17.1) <0.001
Table 4: Best cut-off values as determined by the Youden index.
Threshold Specificity Sensitivity
Peak 33.34 1.0 0.92
TTP 37.8 1.0 0.46
RBV 1910.2 1.0 0.85
RBF 48.4 0.86 0.92
with no significant differences between benign andmalignant
lesions.
Receiver operating curves (ROC)were generated for RBV,
RBF, Peak, andTTP.Thenonparametric estimated ROC areas
were 0.97, 0.96, 0.98, and 0.76, respectively. The best cut-
off points were determined by the Youden index. They were
33.34, 37.8, 1910.2, and 48.4 for Peak, TTP, RBV, and RBF,
respectively (Table 4).
5. Discussion
Hepatic lesions show tumor-specific microvascularization
patterns, which can be demonstrated using CEUS [5]. Unlike
ceCT and ceMRI, it is possible to see a continuous analysis of
microvascularization from the early-arterial phase to the late
phase using CEUS as shown in this pilot study. In ceCT and
ceMRI, this analysis can only be done in sequences and not
continuously.
Most malignant tumors show characteristic perfusion
patternswith a hyperenhancement (HCC; see Figure 1) or rim
enhancement (metastasis, CCC) in the arterial phase [5, 15]
and a washout with a non-/hypoenhancement in the portal-
venous and late venous phases [5, 16]. The arterial perfusion
pattern of HCC is also due to arteriovenous (AV) shunts [17].
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Figure 1: Typical HCC showing a washout starting in the portal-
venous phase in B-mode US and CEUS with the corresponding
time-intensity curve.
Benign lesions can sometimes show a typical pattern of
vascularization in the arterial and portal-venous phases. A
peripheral-nodular enhancement with subsequent filling can
be seen in haemangioma [18], a so-calledwheel-spoke pattern
in focal nodular hyperplasia and a progressive enhancement
from the borders to the center in adenoma [16]. Most
benign lesions show no washout with hyper- or less often
isoenhancement in the portal-venous and late venous phases
[5].
The enhancedmicrovascularization patterns can not only
be visually analyzed and described but also be quantified. A
time-intensity curve (TIC) is essential for the quantification.
This was continuously performed during this pilot study and,
for the first time, over a fixed period of 3 minutes. Perfusion
parameters that describe the course of the curve can be
derived from the TIC. These analyses can be performed
independently and show a high intra- and interobserver
agreement [19]. In this study, wewere able to show differences
in the perfusion parameters Peak, RBV, and RBF that are
helpful in distinguishing benign lesions from malignant
lesions, thus being valuable in differential diagnosis.
Peak signal intensity (in dB) is the maximum signal
intensity reached during the transit of the contrast media.
This was significantly greater in benign lesions than in
malignant lesions. This concurs with the study findings of
Peix et al. [20], who noted a significantly higher Peak in
FNH than in HCC. However, a study in mice found that the
peak signal intensity (as well as TTP) highly depends on the
contrast medium injection speed [21].
TheRBVon the other handwas definitelymore stable and
did not varywith changes in injection speed of contrastmedia
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Figure 2: Time-intensity curve of 5 HCCs and 4 haemangiomas
after local polynomial regression fitting using LOESS. RBV and RBF
are directly proportional to the area under the curve and, therefore,
benefit from a continuous registration to the late phase.
[21]. Benign lesions typically show a steady plateau after
reaching the peak in the TIC.This can be explained with their
hyperenhancement in the late phase and delayed washout
[5, 22]. On the other hand, malignant lesions typically show
a hypoenhancement in the late phase; that is, TIC decreases
soon after the Peak is attained (see Figure 2). RBV and RBF
are directly proportional to the area under the TIC [19].
Therefore, in order to highlight the accuracy of RBV and RBF
as diagnostic tools, we believe it is important to capture data
until the late phase.
There were different limitations in our present study such
as using a heterogeneous collection of different entities of
liver tumors or the perfusion software which is not anywhere
available. Due to technical limitations, images can only be
stored continuously for up to 3 minutes even on high-end
ultrasound machines. Further studies with new machines
may extend this time frame and further improve the accuracy
of perfusion quantification. An experienced examiner and
the special technology are fundamental for this ultrasound
technique. Another limitation is that the described vascular
patterns can only be seen in a part of the lesions depending
on the amount of necrosis.
RBV, RBF, and Peak of CEUS in benign and malignant
liver tumors, continuously measured over a determined
time period of 3 minutes, were significantly different and
show high specificity and sensitivity as classifiers. Therefore,
quantification of long time perfusion could be valuable in dif-
ferentiating benign from malignant liver tumors. This opens
the field for further dynamic investigations of microvascular-
ization of liver tumors in multicenter studies.
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